Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.59, $0.17 better than the analyst estimate of $2.42. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $976 million.

GUIDANCE:

Charles River Laboratories sees FY2024 EPS of $10.10-$10.30, versus the consensus of $10.00.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.